Αρχική World News Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line... World News Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Από Ogkologos - 11 Αυγούστου, 2026 216 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMMIT study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR The Taylor Family Foundation gives £2.1m to support head and neck... 12 Δεκεμβρίου, 2022 Feasibility and Preliminary Efficacy Results of the Beat AML Study 28 Οκτωβρίου, 2020 Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who... 22 Οκτωβρίου, 2019 A new approach to cancer immunotherapy 18 Μαρτίου, 2022 Φόρτωση περισσοτέρων HOT NEWS 关于肺癌生物标志物检测应当了解的信息:专家问答 Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Trial Results Support SBRT as a Standard Option for Some Prostate... 7 Tips For Keeping The Entire Family Healthy During Flu Season